U.S. Biotech Industry Analysis
UpdatedApr 26, 2024
DataAggregated Company Financials
Companies580
- 7D0.4%
- 3M-4.2%
- 1Y0.9%
- YTDn/a
In the last week, the Biotech industry is flat overall, with BioMarin Pharmaceutical standing out by going down 8.8%. In line with that, the industry has also been flat over the past 12 months. As for the next few years, earnings are expected to grow by 21% per annum.
Industry Valuation and Performance
Has the U.S. Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Fri, 26 Apr 2024 | US$1.1t | US$164.2b | -US$23,382,193,080.97 | 20.1x | -46x | 6.6x |
| Sun, 24 Mar 2024 | US$1.2t | US$164.3b | -US$23,936,586,653.35 | 21.4x | -48.6x | 7.1x |
| Tue, 20 Feb 2024 | US$1.2t | US$169.1b | -US$20,394,485,082.32 | 15.7x | -57.5x | 6.9x |
| Thu, 18 Jan 2024 | US$1.4t | US$204.8b | -US$22,506,707,794.00 | 18.8x | -63.3x | 7x |
| Sat, 16 Dec 2023 | US$1.4t | US$204.7b | -US$22,119,635,723.00 | 19.2x | -61x | 6.6x |
| Mon, 13 Nov 2023 | US$1.2t | US$204.5b | -US$21,996,116,562.00 | 18.5x | -54.6x | 5.9x |
| Wed, 11 Oct 2023 | US$1.3t | US$207.4b | -US$13,069,383,940.00 | 17.3x | -96.7x | 6.1x |
| Fri, 08 Sep 2023 | US$1.3t | US$207.5b | -US$12,639,999,993.00 | 17.3x | -100.8x | 6.1x |
| Sun, 06 Aug 2023 | US$1.3t | US$210.2b | -US$10,135,599,050.00 | 15.6x | -124.3x | 6x |
| Tue, 04 Jul 2023 | US$1.1t | US$186.3b | -US$16,037,705,056.00 | 13.4x | -69.9x | 6x |
| Thu, 01 Jun 2023 | US$1.1t | US$185.9b | -US$16,012,100,305.00 | 11.4x | -69.8x | 6x |
| Sat, 29 Apr 2023 | US$1.2t | US$197.1b | -US$6,647,559,484.00 | 13.7x | -174.1x | 5.9x |
| Mon, 27 Mar 2023 | US$1.1t | US$199.3b | -US$3,667,886,514.00 | 13.4x | -309x | 5.7x |
| Wed, 22 Feb 2023 | US$1.1t | US$202.5b | -US$166,298,506.00 | 16.4x | -6829.5x | 5.6x |
| Fri, 20 Jan 2023 | US$1.2t | US$203.7b | US$1.8b | 14.2x | 658.6x | 5.7x |
| Sun, 18 Dec 2022 | US$1.2t | US$203.3b | US$1.6b | 14.4x | 712.9x | 5.7x |
| Tue, 15 Nov 2022 | US$1.1t | US$202.2b | US$1.1b | 14.9x | 1009.4x | 5.5x |
| Thu, 13 Oct 2022 | US$1.0t | US$205.9b | US$5.3b | 15.2x | 195.3x | 5x |
| Sat, 10 Sep 2022 | US$1.1t | US$206.4b | US$6.2b | 15.6x | 177.5x | 5.3x |
| Mon, 08 Aug 2022 | US$1.1t | US$211.4b | US$8.4b | 16.7x | 131.8x | 5.3x |
| Wed, 06 Jul 2022 | US$1.1t | US$211.7b | US$10.9b | 16.8x | 98.6x | 5.1x |
| Fri, 03 Jun 2022 | US$994.0b | US$212.5b | US$11.1b | 15.2x | 89.4x | 4.7x |
| Sun, 01 May 2022 | US$1.0t | US$200.4b | US$6.7b | 16.9x | 151.5x | 5.1x |
| Tue, 29 Mar 2022 | US$1.3t | US$221.5b | US$11.8b | 19.1x | 107.6x | 5.7x |
| Thu, 24 Feb 2022 | US$1.2t | US$216.0b | US$6.3b | 21.3x | 193.4x | 5.6x |
| Sat, 22 Jan 2022 | US$1.2t | US$212.0b | US$2.5b | 23.1x | 493.9x | 5.8x |
| Mon, 20 Dec 2021 | US$1.5t | US$211.9b | US$2.8b | 26.1x | 524x | 6.9x |
| Wed, 17 Nov 2021 | US$1.5t | US$212.2b | US$3.8b | 26.9x | 383.5x | 6.9x |
| Fri, 15 Oct 2021 | US$1.5t | US$196.3b | -US$2,594,144,740.00 | 23.8x | -571.3x | 7.5x |
| Sun, 12 Sep 2021 | US$1.6t | US$196.4b | -US$2,267,737,004.56 | 21.1x | -697.6x | 8.1x |
| Tue, 10 Aug 2021 | US$1.6t | US$197.0b | -US$1,565,512,785.58 | 22.6x | -1020.3x | 8.1x |
| Mon, 03 May 2021 | US$1.4t | US$174.8b | -US$11,096,405,382.55 | 22.2x | -127.4x | 8.1x |
Price to Earnings Ratio
-127.4x
Current Industry PE
- Investors are relatively neutral on the American Biotechnology industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.2x.
Past Earnings Growth
- The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
- Revenues have also declined 2.1% per year.
- This means overall sales from these companies are declining and losses are subsequently expanding as well.
Industry Comparison
How does U.S. Biotech compare with similar industries?
| US Market | 0.97% | |
| Healthcare | 0.76% | |
| Biotech | 0.40% | |
| Biotech | 0.40% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| ABBV AbbVie | US$167.29 | 1.6% +US$4.7b | 12.4% | PE61.5x | |
| AMGN Amgen | US$269.38 | 2.5% +US$3.6b | 12.1% | PE21.5x | |
| SGEN Seagen | US$228.74 | 4.5% +US$1.8b | 76.5% | PS18.8x | |
| BIIB Biogen | US$202.46 | 6.3% +US$1.8b | -31.1% | PE25.3x | |
| BGNE BeiGene | US$148.56 | 12.6% +US$1.7b | -41.9% | PS6.3x |
